This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn  

Exscientia & Sanofi Establish Collaboration to Develop AI-driven Pipeline of Medicines

Exscientia & Sanofi Establish Collaboration to Develop AI-driven Pipeline of Medicines

07 Jan 2022

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines January 7, 2022 * Collaborative efforts aim to accelerate drug discovery and improve clinical success * Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection * Research will be focused on up to 15 novel small molecule... Read more

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

06 Jan 2022

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been appointed Non-Executive Chair of Oxford Cancer Biomarkers Ltd.  She will take a leading role in helping the company achieve its growth and funding goals at a pivotal stage of the business, building on the two recent commercial launches of cancer... Read more

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

05 Jan 2022

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the first patient had been dosed in a first-in-human clinical investigation (ISRCTN17598292) evaluating its proprietary SonoTran® Platform. SonoTran is being evaluated in a... Read more

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform

24 Dec 2021

Sensyne Health announces one year agreement with Exscientia to utilise real-world data platform Agreement includes an upfront payment for four SENSIGHT subscriptions and associated professional services Oxford, U.K. – 24th December 2021 Sensyne Health plc (LSE:SENS or “the Company”) today announced a one-year agreement with Exscientia to leverage the deep learning AI capabilities of the Sensyne platform to study real-world... Read more

OrganOx receives FDA approval for metra device

OrganOx receives FDA approval for metra device

20 Dec 2021

OrganOx receives FDA approval for metra device OrganOx, a world leader in normothermic machine perfusion (NMP), today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its metra system. The OrganOx metra is a fully automated NMP device for the preservation and transport of donor livers destined for transplantation. The marketing approval includes both livers... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More